Tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-based therapy is currently evaluated in clinical studies as a tumor cell selective pro-apoptotic agent. TRAIL induces apoptosis in a number of cancer cell lines while displaying minimal or no toxicity on normal cells. Moreover, TRAIL can activate mitogen-activated protein kinases (MAPKs) in addition to caspases. However, it is not clearly understood how MAPKs are activated by TRAIL and the biological significance of their activation. Our current study demonstrates for the first time that TRAIL induces JNK and p38 MAPK in prostate cancer cells.

**Results and Conclusions**

TRAIL-induced p38MAPK and JNKMAPK activation. We determined whether Ad.TRAIL caused activation of the MAPK pathway in prostate cancer cells. Ad.TRAIL infection caused activation of p38 MAPK (Fig. 2), and JNK MAPK, in prostate DU145.

**Reference**


Acknowledgments

I would like to thank the STEM Scholars Program at Lehman College for this opportunity, with special thanks to Dr. Neil Philip (Bronx Community College) and Dr. Joseph Rachlin (Lehman College). I would also like to thank my mentor, Professor Moira Sauane for letting me be part of her experiment and for going out of her way to help me in anything I needed.